Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Optimized Neurotensin Analogues for the Imaging and Treatment of Advanced Prostate Cancer

FY 2019-20

Summary
"Radioactively-labelled drugs that are engineered to bind preferentially to cancer cells over healthy tissue are a powerful and versatile strategy for non-invasively imaging and treating tumors. The biologically active component of the drug interacts with specific markers on the surface of cancer cells, while the attached radioactive tag can either produce detectable signals for imaging tumors or deliver highly localized, irradiative damage. This diagnostic and treatment platform would greatly benefit patients with late-stage prostate cancers that that have progressed to neuroendocrine prostate carcinomas (NEPCs), as they change their expression patterns to be unresponsive to existing androgen-deprivation therapies, reaching an incurable state with poor clinical outcomes. A key biomarker overexpressed in NEPCs is neurotensin receptor 1 (NTSR1), which binds the 13 amino acid peptide neurotensin (NTS) and facilitates androgen-independent tumoral growth. Several NTS-based radiopharmaceuticals have been developed, but suffer from poor biological stability due to rapid enzymatic degradation as well as high kidney accumulation. Thus, to make them efficacious as imaging agents and radiotherapeutics, our goal is to generate new NTSR1-binding peptides that employ biologically stabilizing modifications to the NTS sequence while retaining high binding affinity. Optimization of the linker region of the drug, which connects the biologically active and radioactive components, will improve tumor uptake that is beneficial for both image contrast and therapy. These candidate drugs will be assessed in prostate cancer mouse models expressing NTSR1 by monitoring their tumor localization and delivery of radioactivity, and may produce novel diagnostics and therapeutics for NEPC."
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428815
Name
Fraser Bryan
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Optimized Neurotensin Analogues for the Imaging and Treatment of Advanced Prostate Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Imaging; Drug Design; Endoradiotherapy; Peptides; Pet; Pre-Clinical Studies; Prostate Cancer; Radiopharmaceuticals
Abstract
"Radioactively-labelled drugs that are engineered to bind preferentially to cancer cells over healthy tissue are a powerful and versatile strategy for non-invasively imaging and treating tumors. The biologically active component of the drug interacts with specific markers on the surface of cancer cells, while the attached radioactive tag can either produce detectable signals for imaging tumors or deliver highly localized, irradiative damage. This diagnostic and treatment platform would greatly benefit patients with late-stage prostate cancers that that have progressed to neuroendocrine prostate carcinomas (NEPCs), as they change their expression patterns to be unresponsive to existing androgen-deprivation therapies, reaching an incurable state with poor clinical outcomes. A key biomarker overexpressed in NEPCs is neurotensin receptor 1 (NTSR1), which binds the 13 amino acid peptide neurotensin (NTS) and facilitates androgen-independent tumoral growth. Several NTS-based radiopharmaceuticals have been developed, but suffer from poor biological stability due to rapid enzymatic degradation as well as high kidney accumulation. Thus, to make them efficacious as imaging agents and radiotherapeutics, our goal is to generate new NTSR1-binding peptides that employ biologically stabilizing modifications to the NTS sequence while retaining high binding affinity. Optimization of the linker region of the drug, which connects the biologically active and radioactive components, will improve tumor uptake that is beneficial for both image contrast and therapy. These candidate drugs will be assessed in prostate cancer mouse models expressing NTSR1 by monitoring their tumor localization and delivery of radioactivity, and may produce novel diagnostics and therapeutics for NEPC."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fraser, Bryan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~